Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review☆☆☆
Sign Up to like & getrecommendations! Published in 2019 at "Anais Brasileiros de Dermatologia"
DOI: 10.1016/j.abd.2019.01.009
Abstract: Topical use of immune response modifiers, such as imiquimod, has increased in dermatology. Although its topical use is well tolerated, it may be associated with exacerbations of generalized cutaneous inflammatory diseases, possibly through the systemic… read more here.
Keywords: use; pityriasis rubra; rubra pilaris; topical use ... See more keywords
A practical guide on the use of imiquimod cream to treat lentigo maligna
Sign Up to like & getrecommendations! Published in 2021 at "Australasian Journal of Dermatology"
DOI: 10.1111/ajd.13720
Abstract: Lentigo maligna (LM) is a common in situ melanoma subtype arising on chronically sun‐damaged skin and mostly affects the head and neck region. Localisation in cosmetically sensitive areas, difficulty to obtain wide resection margins and… read more here.
Keywords: treat; lentigo maligna; use imiquimod; imiquimod cream ... See more keywords
Real‐world experience of off‐label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20407
Abstract: Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by… read more here.
Keywords: real world; lentigo maligna; experience label; label use ... See more keywords